GlassScriptPhysician profile
Eduardo Martinez
NPI 1265789366
$7,861.14
in general payments reported to CMS, 2019-2025
27 companies · $516 in 2025
The $516 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $284 · 2021: $194 · 2022: $224 · 2023: $302 · 2024: $5,942 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,500 · Food and Beverage: $1,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,500.00 |
| Food and Beverage | $1,259.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,636.99 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $330.22 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $312.59 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $266.86 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Insmed, INC. | $215.76 | 2019-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $177.19 | 2019-2025 | Dupixent |
| Genzyme Corporation | $133.36 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $118.48 | 2022-2024 | Uptravi, Opsumit |
| Grifols USA, LLC | $108.02 | 2019-2025 | Prolastin-C Liquid |
| Harmony Biosciences LLC | $102.83 | 2020-2023 | Wakix |
| Mylan Specialty L.P. | $46.16 | 2019-2023 | Yupelri |
| Abbvie INC. | $45.92 | 2023-2024 | |
| Sunovion Pharmaceuticals INC. | $42.46 | 2019 | |
| Livanova USA, INC. | $39.02 | 2022 | |
| Pfizer INC. | $38.90 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $34.85 | 2023-2024 | Fetroja |
| Janssen Pharmaceuticals, INC | $25.70 | 2021 | |
| Mallinckrodt Enterprises LLC | $24.55 | 2019 | |
| Baxter Healthcare | $22.41 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Viatris Specialty LLC | $21.33 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $19.53 | 2023 | Glassia |
| Daiichi Sankyo INC. | $18.81 | 2019 | |
| Shire North American Group INC | $17.92 | 2019 | |
| Philips North America LLC | $17.54 | 2020 | |
| Advanced Respiratory, INC | $15.98 | 2021 | |
| Lilly USA, LLC | $15.65 | 2025 | Zepbound |
| Inogen, INC. | $12.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.